Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction.
10.3343/alm.2018.38.6.538
- Author:
Hyun Jung CHOI
1
;
Min Chul KIM
;
Doo Sun SIM
;
Young Joon HONG
;
Ju Han KIM
;
Myung Ho JEONG
;
Soo Hyun KIM
;
Myung Geun SHIN
;
Youngkeun AHN
Author Information
1. Departments of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea. mgshin@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Copeptin;
Prognosis;
Major adverse cardiac events;
Myocardial infarction;
Percutaneous coronary intervention
- MeSH:
Coronary Artery Bypass;
Follow-Up Studies;
Humans;
Incidence;
Logistic Models;
Myocardial Infarction*;
Percutaneous Coronary Intervention*;
Prognosis;
Retrospective Studies
- From:Annals of Laboratory Medicine
2018;38(6):538-544
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI. METHODS: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated. RESULTS: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005). CONCLUSIONS: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.
